公司概述
Jackson Acquisition Company II (JACS) operates as a special purpose acquisition company (SPAC) designed to facilitate a business combination with target entities within the healthcare industry, rather than engaging in significant standalone operations. The company is classified within the Financial Services sector and specifically within the Shell Companies industry, which distinguishes its primary objective of raising capital for future mergers or asset acquisitions from standard operating businesses. As of the latest data, the firm holds a market capitalization of $312.17M, while reported annual revenue is not available (N/A), and the employee count is listed as N/A. These valuation figures indicate that the company's current market price is driven almost exclusively by its potential future transaction value and the prospectus of a pending healthcare deal, rather than by historical earnings power or established revenue streams typical of mature financial institutions.
财务健康
The financial performance of Jackson Acquisition Company II shows a Net Income of $9.12M over the trailing twelve months (TTM), while Revenue and EBITDA figures are not available (N/A) due to the SPAC structure. The absence of reported revenue relative to the positive Net Income reveals a cost structure where non-operating income or specific accounting treatments related to the shell company status contribute to profitability without traditional sales activity. The company reports a Free Cash Flow of $-298,680, which indicates a net outflow of cash that reflects the typical operational setup of a SPAC awaiting a merger rather than a sustainable cash generation model for the immediate future. All three margin metrics—Gross Margin, Operating Margin, and Profit Margin—are recorded at 0.0%, which signifies that the company has not yet generated significant gross profits from operations to cover its direct costs or operating expenses in a traditional commercial context. Regarding liquidity and leverage, the company holds $521,776 in cash against a total debt obligation of $198,024, resulting in a Debt to Equity ratio of 89.70, which suggests a leveraged balance sheet typical for SPACs preparing for capital-intensive mergers. The Current Ratio stands at 1.53, indicating that the company possesses sufficient short-term assets to cover its short-term liabilities, providing a conservative buffer for upcoming transaction costs. Furthermore, the Return on Equity (ROE) is reported at an anomalous 1804.0%, while the Return on Assets (ROA) is -0.1%; these divergent metrics highlight the unique financial engineering and low asset base characteristic of shell companies, where equity is often minimal relative to the market cap, inflating the ROE calculation.
估值评估
Jackson Acquisition Company II carries a Trailing Twelve Months (TTM) Price to Earnings (P/E) ratio of 34.03, whereas the Forward P/E is not available (N/A), implying that the market is currently valuing the company based on past earnings rather than projected future earnings growth from a completed merger. The Price to Book ratio is extremely high at 1507.14, which indicates a massive market premium over the company's book value, reflecting the speculative nature of SPACs where the market price vastly exceeds the net asset value of the trust. Alternative valuation metrics such as Price to Sales and EV/EBITDA are not available (N/A), suggesting that traditional valuation models are less applicable given the lack of significant revenue or earnings generation at this stage. The stock has traded between a 52-Week High of $10.60 and a 52-Week Low of $10.05, meaning the current trading price sits at the lower end of this recent range, specifically hovering near the 52-week low. The Beta value is not available (N/A), which prevents a direct comparison of price volatility relative to the broader market, though the high P/E and price-to-book ratios inherently suggest elevated risk and sensitivity to merger completion timelines.
Growth & Income
Revenue Growth and Earnings Growth over the year-over-year period are both not available (N/A), which is consistent with the company's status as a shell entity without significant historical operations to provide a growth trajectory for comparison. Since the company does not pay a dividend, with a Dividend Yield and Payout Ratio both listed as not available or 0.0%, it does not distribute cash to shareholders, implying that any generated earnings are theoretically available for reinvestment or accumulation within the SPAC trust structure. Consequently, the company's strategy focuses entirely on capitalizing on a future business combination rather than providing income through dividends or demonstrating organic growth through sales expansion. Overall, the growth and income profile is defined by the potential for a single transformative event rather than steady organic expansion or dividend income, creating a high-risk, high-reward dynamic centered on the execution of a healthcare industry merger.